Here - EWMA 2013

SESSION ROOM C3 ROOM B1 ROOM 18 ROOM 19Workshop:Meet the experts in maggot therapyChairs: F. Gottrup, G. Jukema97. F. Gottrup: Maggot therapy in a woundhealing centre98. G. Jukema: Maggots: the (re)search forevidence99. W. Fleischman: Maggots for treatmentof trauma injuries100. T. Karlsmark: Changes in thesurrounding skin when treating with maggotsDiabetic foot symposiumInternational perspectives onimplementationChair: Mauri LäpentaloA. Piaggesi: ItalyJ. Aragón Sánchez: SpainPanel discussion: Nordic Perspective– What are the most urgent steps to betaken to move the implementationagenda forwards?Satellite symposium:A quiz: Treating hard-to-heal woundswith a new generation of products.How? When? Why?Chair: R. WhiteJ. HaikK. BernaertsSatellite symposium:Dechronification with PolyHeal– A solution for problematic woundsChair: L. TéotS. Davis: Negatively ChargedMicrospheres (NCM)-Technology:A novel approach to treat non-healingwoundsR. Peters: Evidence-based medicine:Clinical effect ofwound dechronificationwith PolyHealTBA: Personal experience withPolyHeal in problematic acute woundsSatellite symposium:Keeping us safe; the link between safepatient handling, nurse injury andhealthcare acquired pressure ulcersChair: M. ClarkE. Hall: How the Stanford ERM modeldemonstrates the economics of safe patienthandling. What it tells us about futureintervention strategies and their potential?M. Humrickhouse: How Diligent hascontributed to MCHC’s success. How UShealthcare changes in value based purchasingincrease the focus upon Never Events. Howemphasising safe patient handling can begood for preventing pressure ulcers?H. Knibbe: How current research is looking anearly mobilisation, safe patient handling withtissue viability. How these approaches couldbe taken to reduce HAPU in Europe.Sponsored by Flen PharmaSponsored by Medi WoundSponsored by ArjoHuntleighKey Session:Recent evidence – Vascularisationand amputationChairs: J. Apelqvist, J. Aragón Sánchez105. G. Rümenapf: Revascularisationin the diabetic foot: why is a multidisciplinaryapproach essential?106. R. Hinchliffe: Revascularisationof the ischemic diabetic foot ulcer –where is the evidence107. M. Lepäntalo: When torevascularize?108. T. Elgzyri: Factors related tooutcome of neuroischemic/ ischemicfoot ulcer in diabetic patientsWorkshop:Dressings and topical agentsJ. Jordan O’BrienWorkshop:Pressure ulcer prevention andpressure redistributionM. Van EttenWorkshop:BiofilmT. Bjarnsholt: The role of biofilms in chronicwoundsR. Cooper: Anti biofilm treatment strategiesM. Alhede: How and why to test anti biofilmdrugs13